Correlation Between Adial Pharmaceuticals and Emergent Biosolutions

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Adial Pharmaceuticals and Emergent Biosolutions at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Adial Pharmaceuticals and Emergent Biosolutions into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Adial Pharmaceuticals and Emergent Biosolutions, you can compare the effects of market volatilities on Adial Pharmaceuticals and Emergent Biosolutions and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Adial Pharmaceuticals with a short position of Emergent Biosolutions. Check out your portfolio center. Please also check ongoing floating volatility patterns of Adial Pharmaceuticals and Emergent Biosolutions.

Diversification Opportunities for Adial Pharmaceuticals and Emergent Biosolutions

-0.22
  Correlation Coefficient

Very good diversification

The 3 months correlation between Adial and Emergent is -0.22. Overlapping area represents the amount of risk that can be diversified away by holding Adial Pharmaceuticals and Emergent Biosolutions in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Emergent Biosolutions and Adial Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Adial Pharmaceuticals are associated (or correlated) with Emergent Biosolutions. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Emergent Biosolutions has no effect on the direction of Adial Pharmaceuticals i.e., Adial Pharmaceuticals and Emergent Biosolutions go up and down completely randomly.

Pair Corralation between Adial Pharmaceuticals and Emergent Biosolutions

Given the investment horizon of 90 days Adial Pharmaceuticals is expected to generate 1.02 times more return on investment than Emergent Biosolutions. However, Adial Pharmaceuticals is 1.02 times more volatile than Emergent Biosolutions. It trades about 0.18 of its potential returns per unit of risk. Emergent Biosolutions is currently generating about 0.05 per unit of risk. If you would invest  101.00  in Adial Pharmaceuticals on September 18, 2024 and sell it today you would earn a total of  12.00  from holding Adial Pharmaceuticals or generate 11.88% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Adial Pharmaceuticals  vs.  Emergent Biosolutions

 Performance 
       Timeline  
Adial Pharmaceuticals 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Adial Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain forward indicators, Adial Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in January 2025.
Emergent Biosolutions 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Emergent Biosolutions are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent fundamental drivers, Emergent Biosolutions unveiled solid returns over the last few months and may actually be approaching a breakup point.

Adial Pharmaceuticals and Emergent Biosolutions Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Adial Pharmaceuticals and Emergent Biosolutions

The main advantage of trading using opposite Adial Pharmaceuticals and Emergent Biosolutions positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Adial Pharmaceuticals position performs unexpectedly, Emergent Biosolutions can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will offset losses from the drop in Emergent Biosolutions' long position.
The idea behind Adial Pharmaceuticals and Emergent Biosolutions pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Other Complementary Tools

Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Global Correlations
Find global opportunities by holding instruments from different markets
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.